Summit 2008
The 2008 North American Thrombosis Summit was held Saturday, September 27, 2008, at the Fairmont Copley Plaza Hotel in Boston, Massachusetts. Targeted to physicians, nurses, physician assistants, pharmacists, hospitalists, and hospital administrators interested in thrombosis treatment and prevention, the intensive 1-day symposium included talks from 15 renowned leaders in the field of thrombosis, including physicians, nurses, pharmacists, and basic researchers.
Lecture guides are available below:
Translational Research
Pharmacogenomics of Warfarin: Are the Promises Justified?
Brian F. Gage, MD, MSc
Heparin-Induced Thrombocytopenia: Controversies and Updates
Jeanine M. Walenga, PhD
Clinical Research
Controversies Surrounding the Optimal Therapy of Extensive Leg DVT
Suresh Vedantham, MD
Bar-Coding Inpatient Medications to Improve Patient Safety
John Fanikos, RPh, MBA
Unfractionated and LMWH: Safety and Regulatory Concerns
Jawed Fareed, PhD
Estrogen and Thrombosis: A Women's Health Issue
JoAnn E. Manson, MD, DrPH
The 10 Most Important Advances in Thrombosis Understanding During the Last 50 Years...with apologies to David Letterman
Joseph S. Alpert, MD
Prevention and Education
Anticoagulation Management and Warfarin Safety: A Systems Approach
Allen Kachalia, MD, JD
Anticoagulation Bridging: Hope or Hype
Samuel Z. Goldhaber, MD
Prevention of Stroke
Mary Amatangelo, RN, MS, APRN-BC, CCRN
Prevention of Venous Thromboembolism: Can Computers Help?
Karen Fiumara, PharmD
Thrombosis and Cancer
Craig M. Kessler, MD
Public Policy and Advocacy
Policies to Prevent and Minimize the Burden of CHD
Deepak I. Bhatt, MD
The National Heart, Lung and Blood Institute
Susan B. Shurin, MD (Deputy Director, NHLBI)
Summary of VIP Thrombosis Working Group Discussion 2008
Outreach
As a multi-disciplinary organization it is imperative that NATF reach out to the various stakeholders of thrombosis and cardiovascular disease. On September 26, 2008, NATF held a VIP Thrombosis Leadership Working Group Discussion focused on the subject of “Outreach.” The list of discussants reflects NATF’s multi-disciplinary approach for providing tools to break down and integrate traditional “silos.” As such, well-known representatives from various “silos” were invited, including: clinical and research physicians, scientists, nurses, pharmacists, patients/caregivers, and policy makers.
Discussion group attendees were asked to discuss two questions, both related to Outreach: 1) Who should be the target audience?, and 2) What would be the best approach/methodology to outreach these audiences? The same questions were asked within each of NATF’s five areas of focus: Basic/Translational Research; Clinical Research; Prevention/Education; Public Policy, and Advocacy. The multi-disciplinary dialog enabled participants to learn from each other while beginning the task of creating a collaborative action plan to address this important issue.
The outcome of this conversation is summarized below.
NATF should take a leadership role in:
- Emphasizing the importance of basic research
- Setting a research agenda
- Educating the general public
- Developing consensus guidelines through interdisciplinary networks
- Educating healthcare professionals